332 related articles for article (PubMed ID: 25825013)
21. The effects of GLP-1 analogues in obese, insulin-using type 2 diabetes in relation to eating behaviour.
de Boer SA; Lefrandt JD; Petersen JF; Boersma HH; Mulder DJ; Hoogenberg K
Int J Clin Pharm; 2016 Feb; 38(1):144-51. PubMed ID: 26597956
[TBL] [Abstract][Full Text] [Related]
22. Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults With Overweight or Obesity and Type 2 Diabetes: A 54-Week Randomized Phase 2b Study.
Nahra R; Wang T; Gadde KM; Oscarsson J; Stumvoll M; Jermutus L; Hirshberg B; Ambery P
Diabetes Care; 2021 Jun; 44(6):1433-1442. PubMed ID: 34016612
[TBL] [Abstract][Full Text] [Related]
23. Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue.
Jendle J; Nauck MA; Matthews DR; Frid A; Hermansen K; Düring M; Zdravkovic M; Strauss BJ; Garber AJ;
Diabetes Obes Metab; 2009 Dec; 11(12):1163-72. PubMed ID: 19930006
[TBL] [Abstract][Full Text] [Related]
24. Adding liraglutide to lifestyle changes, metformin and testosterone therapy boosts erectile function in diabetic obese men with overt hypogonadism.
Giagulli VA; Carbone MD; Ramunni MI; Licchelli B; De Pergola G; Sabbà C; Guastamacchia E; Triggiani V
Andrology; 2015 Nov; 3(6):1094-103. PubMed ID: 26447645
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of liraglutide monotherapy compared with metformin in Japanese overweight/obese patients with type 2 diabetes.
Tanaka K; Saisho Y; Kawai T; Tanaka M; Meguro S; Irie J; Imai T; Shigihara T; Morimoto J; Yajima K; Atsumi Y; Takei I; Itoh H
Endocr J; 2015; 62(5):399-409. PubMed ID: 25739726
[TBL] [Abstract][Full Text] [Related]
26. Effect of immediate and prolonged GLP-1 receptor agonist administration on uric acid and kidney clearance: Post-hoc analyses of four clinical trials.
Tonneijck L; Muskiet MHA; Smits MM; Bjornstad P; Kramer MHH; Diamant M; Hoorn EJ; Joles JA; van Raalte DH
Diabetes Obes Metab; 2018 May; 20(5):1235-1245. PubMed ID: 29341461
[TBL] [Abstract][Full Text] [Related]
27. Antisense Inhibition of Protein Tyrosine Phosphatase 1B With IONIS-PTP-1B
Digenio A; Pham NC; Watts LM; Morgan ES; Jung SW; Baker BF; Geary RS; Bhanot S
Diabetes Care; 2018 Apr; 41(4):807-814. PubMed ID: 29439147
[TBL] [Abstract][Full Text] [Related]
28. One-year follow-up on liraglutide treatment for prediabetes and overweight/obesity in clozapine- or olanzapine-treated patients.
Svensson CK; Larsen JR; Vedtofte L; Jakobsen MSL; Jespersen HR; Jakobsen MI; Koyuncu K; Schjerning O; Nielsen J; Ekstrøm CT; Correll CU; Vilsbøll T; Fink-Jensen A
Acta Psychiatr Scand; 2019 Jan; 139(1):26-36. PubMed ID: 30374965
[TBL] [Abstract][Full Text] [Related]
29. Addition of a dipeptidyl peptidase-4 inhibitor, sitagliptin, to ongoing therapy with the glucagon-like peptide-1 receptor agonist liraglutide: A randomized controlled trial in patients with type 2 diabetes.
Nauck MA; Kahle M; Baranov O; Deacon CF; Holst JJ
Diabetes Obes Metab; 2017 Feb; 19(2):200-207. PubMed ID: 27709794
[TBL] [Abstract][Full Text] [Related]
30. rs6923761 gene variant in glucagon-like peptide 1 receptor: Allelic frequencies and influence on cardiovascular risk factors in a multicenter study of Castilla-Leon.
de Luis DA; Ballesteros M; Lopez Guzman A; Ruiz E; Muñoz C; Penacho MA; Iglesias P; Maldonado A; Puigdevall V; Delgado M
Clin Nutr; 2018 Dec; 37(6 Pt A):2144-2148. PubMed ID: 29128339
[TBL] [Abstract][Full Text] [Related]
31. Once-Weekly Efpeglenatide Dose-Range Effects on Glycemic Control and Body Weight in Patients With Type 2 Diabetes on Metformin or Drug Naive, Referenced to Liraglutide.
Rosenstock J; Sorli CH; Trautmann ME; Morales C; Wendisch U; Dailey G; Hompesch M; Choi IY; Kang J; Stewart J; Yoon KH
Diabetes Care; 2019 Sep; 42(9):1733-1741. PubMed ID: 31320446
[TBL] [Abstract][Full Text] [Related]
32. Effects of GLP-1 receptor agonists on asprosin levels in normal weight or overweight/obesity patients with type 2 diabetes mellitus.
Dai C; Zhu W
Medicine (Baltimore); 2022 Oct; 101(43):e31334. PubMed ID: 36316938
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight, eating behavior, and glycemic control, in Japanese obese type 2 diabetes.
Fujishima Y; Maeda N; Inoue K; Kashine S; Nishizawa H; Hirata A; Kozawa J; Yasuda T; Okita K; Imagawa A; Funahashi T; Shimomura I
Cardiovasc Diabetol; 2012 Sep; 11():107. PubMed ID: 22973968
[TBL] [Abstract][Full Text] [Related]
34. Liraglutide or insulin glargine treatments improves hepatic fat in obese patients with type 2 diabetes and nonalcoholic fatty liver disease in twenty-six weeks: A randomized placebo-controlled trial.
Guo W; Tian W; Lin L; Xu X
Diabetes Res Clin Pract; 2020 Dec; 170():108487. PubMed ID: 33035599
[TBL] [Abstract][Full Text] [Related]
35. The effect of addition of liraglutide to high-dose intensive insulin therapy: a randomized prospective trial.
Lane W; Weinrib S; Rappaport J; Hale C
Diabetes Obes Metab; 2014 Sep; 16(9):827-32. PubMed ID: 24589127
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of liraglutide 3.0 mg for weight management are similar across races: subgroup analysis across the SCALE and phase II randomized trials.
Ard J; Cannon A; Lewis CE; Lofton H; Vang Skjøth T; Stevenin B; Pi-Sunyer X
Diabetes Obes Metab; 2016 Apr; 18(4):430-5. PubMed ID: 26744025
[TBL] [Abstract][Full Text] [Related]
37. The effects of glucagon-like peptide-1 receptor agonists on glycemic control and anthropometric profiles among diabetic patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis of randomized controlled trials.
Nowrouzi-Sohrabi P; Rezaei S; Jalali M; Ashourpour M; Ahmadipour A; Keshavarz P; Akbari H
Eur J Pharmacol; 2021 Feb; 893():173823. PubMed ID: 33352183
[TBL] [Abstract][Full Text] [Related]
38. Is insulin the most effective injectable antihyperglycaemic therapy?
Buse JB; Peters A; Russell-Jones D; Furber S; Donsmark M; Han J; MacConell L; Maggs D; Diamant M
Diabetes Obes Metab; 2015 Feb; 17(2):145-51. PubMed ID: 25323312
[TBL] [Abstract][Full Text] [Related]
39. GLP-1 Receptor Agonist Treatment in Morbid Obesity and Type 2 Diabetes Due to Pathogenic Homozygous Melanocortin-4 Receptor Mutation: A Case Report.
Iepsen EW; Have CT; Veedfald S; Madsbad S; Holst JJ; Grarup N; Pedersen O; Brandslund I; Holm JC; Hansen T; Torekov SS
Cell Rep Med; 2020 Apr; 1(1):100006. PubMed ID: 33205056
[TBL] [Abstract][Full Text] [Related]
40. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials.
Vilsbøll T; Christensen M; Junker AE; Knop FK; Gluud LL
BMJ; 2012 Jan; 344():d7771. PubMed ID: 22236411
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]